# OnCo record ubx-303061 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ubx-303061/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ubx-303061" ;
  schema:name "UBX-303-1"@en ;
  schema:alternateName "UBX-303061"@en, "BTK Degrader UBX-303061"@en ;
  schema:description "UBX-303-1 is an experimental oral targeted protein degrader from Ubix Therapeutics, in phase 1 trials for relapsed or refractory B-cell malignancies."@en ;
  schema:url <https://onco.cc/drugs/ubx-303061/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://ubixtrx.com/pipeline>, <https://ubixtrx.com/pipeline>, <https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/search?term=UBX-303061&include=definitions,synonyms>, <https://clinicaltrials.gov/api/v2/studies/NCT06590961>, <https://clinicaltrials.gov/search?intr=UBX-303061> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral targeted protein degrader (chimeric degrader; company term 'Degraducer')" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:companies <https://onco.cc/companies/ubix-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct06590961/> .